In this study, we expanded the target population by including patients after treatment and with recurrent bladder cancer to further evaluate the diagnostic performance of VI-RADS. The diagnostic performances of VI-RADS were good in all subgroups including the primary, post-treatment and recurrence groups (AUC > 0.90). No significant differences were observed in diagnostic efficacy of VI-RADS between the primary group and the post-treatment group, and between the primary group and the recurrence group. Overall, this study demonstrated that VI-RADS can be considered an effective preoperative imaging staging tool for a wider range of bladder cancer patients.
This abstract and the presentation materials are available to members only; a login is required.